Skip to main content
SpringerLink
Log in

The Triazolam Experience in 1979 in The Netherlands, a Problem of Signal Generation and Verification

  • Chapter
Drug Epidemiology and Post-Marketing Surveillance

Part of the book series: NATO ASI Series ((NSSA,volume 224))

Abstract

Triazolam (Halcion) was marketed as a hypnotic in the Netherlands early in 1978. There were tablets of three different strengths: 0.25, 0.5, and 1 mg. The product information recommended a dose of “0.25–0.5 mg for elderly patients who have not already been using a sedative or hypnotic drug and 0.5–1 mg for hospitalized patients, psychiatric patients, chronic alcoholics, and patients who were already using other hypnotic or sedative drugs” and included the advice to start in elderly and weakened patients with 0.25 mg. The paragraph on side effects read: “Sedation, hypotension, dizziness, impaired motor coordination, hiccup, headache or nausea are sometimes observed. These side effects usually occur when too high doses are taken.”

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. C. Van der Kroef, Halcion, een onschuldig slaapmiddel?, Ned Tijdschr Geneesk. 123:1160–1 (1979).

    Google Scholar 

  2. C. Van der Kroef, Reactions to triazolam, Lancet. 2:526 (1979).

    Article  PubMed  Google Scholar 

  3. R.H.B. Meyboom, Psychische stoornissen tijdens het gebruik van triazolam (Halcion), Letter to all physicians and pharmacists, 16 juli (1979).

    Google Scholar 

  4. L. Lasagna, The Halcion story: trial by media, Lancet. 1:815–6 (1980).

    Article  PubMed  CAS  Google Scholar 

  5. H. Petursson, and M.H. Lader, Withdrawal from long-term benzodiazepine treatment, Brit Med J. 283:643–5 (1981).

    Article  CAS  Google Scholar 

  6. M. Lader, and H. Petursson, Long-term effects of benzodiazepines, Neuropharmacology. 22:527–33 (1983).

    Article  PubMed  CAS  Google Scholar 

  7. P. Tyrer, D. Rutherford, and T. Huggett, Benzodiazepine withdrawal symptoms and Propranolol, Lancet. 1:520–22 (1981).

    Article  PubMed  CAS  Google Scholar 

  8. P. Tyrer, and R. Owen, Gradual withdrawal of diazepam after long-term therapy, Lancet. 1:1402–6 (1983).

    Article  PubMed  CAS  Google Scholar 

  9. H. Ashton, Benzodiazepine withdrawal: an unfinished story, Brit Med J. 288:1135–40 (1984).

    Article  CAS  Google Scholar 

  10. T.R. Einarson, Hallucinations form triazolam, Drug Intell Clin Pharm. 14:714–5 (1980).

    Google Scholar 

  11. T.R. Einarson, and E.S. Yoder, Triazolam psychosis, Drug Intell Clin Pharm. 16:330 (1982).

    PubMed  CAS  Google Scholar 

  12. B. Trappler, T. Bezeredi, Triazolam intoxication, Can Med Assoc J. 126:893–4 (1982).

    Google Scholar 

  13. A.N. Singh, Chemij, and J. Jewell, Treatment of triazolam dependence with a tapering withdrawal regimen, Can Med Assoc J. 134:243–5 (1986).

    CAS  Google Scholar 

  14. J.W. Mostert, Die Halcion-affere, S Afr Med J. 59:967 (1981).

    PubMed  CAS  Google Scholar 

  15. R. Poitras, A propos d’épisodes d’amnésies antérogrades associés a l’utilisation du triazolam, L’Union Med Canada. 109:427–29 (1980).

    CAS  Google Scholar 

  16. T.L. Tan, E.O. Bixler, A. Kales, R.J. Cadieux, and A.L. Goodman, Early morning insomnia, daytime anxiety, and organic mental disorder associated with triazolam, J Family Practice. 20:592–4 (1985).

    CAS  Google Scholar 

  17. Q.R. Regestein, and P. Reich, Agitation observed during treatment with newer hypnotic drugs, J Clin Psychiatry. 46:280–3 (1985).

    PubMed  CAS  Google Scholar 

  18. C.R. Soldatos, P.N. Sakkas, J.D. Bergiannaki, and C.N. Stefanis, Behavioural side effects of triazolam in psychiatric inpatients: report of five cases, Drug Intell Clin Pharmac. 20:294–7 (1986).

    CAS  Google Scholar 

  19. J.F. Patterson, Triazolam syndrome in the elderly, South Med J 80:1425–6 (1987).

    Article  PubMed  CAS  Google Scholar 

  20. E.O. Bixler, A. Kales, B.H. Brubaker, and J.D. Kales, Adverse reactions to benzodiazepine hypnotics: spontaneous reporting system, Pharmacology. 35:286–300 (1987).

    Article  PubMed  CAS  Google Scholar 

  21. K. Adam and I. Oswald, Triazolam 0,5 mg as an hypnotic causes daytime anxiety.

    Google Scholar 

  22. J.B. Weilburg, G. Sachs, and W.E. Falk, Triazolam-induced brief episodes of secundary mania in a depressed patient, J Clin Psych. 48:492–3 (1987).

    CAS  Google Scholar 

  23. R. Denson, Involuntary self-intoxication with triazolam, Psych J Univ Ottawa. 12:242–3 (1987).

    CAS  Google Scholar 

  24. J.A.E. Flemming, Triazolam abuse, Can Med Assoc J. 129:324–5 (1983).

    Google Scholar 

  25. E.J. Lynn, Triazolam addiction, Hosp Community Psychiatry 36:779–80 (1985).

    PubMed  CAS  Google Scholar 

  26. J.A. Flemming, K. Rungta, and T. Isomura, Withdrawal regimen for triazolam-dependent patients, Can Med Assoc J 134:1230–1 (1986).

    Google Scholar 

  27. K.R. Olson, L. Yin, J. Osterloh, and A. Tani, Coma caused by trivial triazolam overdose, Am J Emerg Med. 3:210–1 (1985).

    Article  PubMed  CAS  Google Scholar 

  28. D. Schneider-Helmert, Dämmerzustände nach dem Hypnotikum Midazolam, Schweiz med Wschr 115:247–9 (1985).

    PubMed  CAS  Google Scholar 

  29. M. Häcki, Amnestische Episoden nach einnahme des Hypnotikums Midazolam, Wirkung oder Nebenwirkung?, Schweiz med Wochenschr. 116:42–4 (1986).

    PubMed  Google Scholar 

  30. B. Poyen, R. Rodor, Jouve-Bestagne, M.C. Galland, R. Lots, and J. Jouglar, Amnésie et troubles comportemantaux d’apparence délictuelle survenus apres ingestion de benzodiazépines, Thérapie 37:675–8 (1982).

    PubMed  CAS  Google Scholar 

  31. J.L. Fouilladieu, J. d’Enfert, M. Zerbib, N. Yegaheg, F. Baudin, and C. Conseiller, Troubles comportementaux secondaires a la prise de benzodiazépines, Presse Méd 14:1009–12 (1985).

    PubMed  CAS  Google Scholar 

  32. A. Kales, J.D. Kales, E.O. Bixler, M.B. Scharf, and E. Russek, Hypnotic efficacy of triazolam: sleep laboratory evaluation of intermediate-term effectiveness, J Clin Pharmacol 16:399–406 (1976).

    Article  PubMed  CAS  Google Scholar 

  33. N. Macleod, Triazolam: monitored release in the United Kingdom, Brit J Clin Pharmacol 11:51S–53S (1981).

    Google Scholar 

  34. A.N. Singh, and B. Saxena, Double-blind cross-over comparison of triazolam and flurazepam in hospitalized psychiatic patients with insomnia, Curr Ther Res Clin Exp. 27:627–34 (1980).

    Google Scholar 

  35. I. Oswald, Criteria for selecting an hypnotic, TGO tijdschrift voor Therapie, Journal for Drugtherapy and Research. 9:480–6 (1984).

    Google Scholar 

  36. H. Ashton, Risk of dependence on benodiazepine drugs: a major problem of long term treatment, Brit Med J. 298:103–4 (1989).

    Article  PubMed  CAS  Google Scholar 

  37. J.F. Rosenbaum, S.W. Woods, J.E. Groves, and G.L. Klerman, Emergence of hostility during alprazolam treatment, Am J Psychiatry. 141:792–3 (1984).

    PubMed  CAS  Google Scholar 

  38. D.L. Gardner, and R.W. Cowdry, Alprazolam-induced dyscontrol in borderline personality disorder, Am J Psychiatry. 142:98–100 (1985).

    PubMed  CAS  Google Scholar 

  39. A. Strahan, J. Rosenthal, M. Kaswan, and A. Winston, Three case reports of acute paroxysmal excitement associated with alprazolam treatment, Am J Psychiatry 142:859–61 (1985).

    PubMed  CAS  Google Scholar 

  40. A. Kales, Benzodiazepine hypnotics and insomnia, Hosp Pract (Off) 25:Suppl 3,7–21, discussion 22-3 (1990).

    Google Scholar 

  41. A.J. Bayer, E.M. Bayer, M.S.J. Pathy, and M.J. Stoker, A double-blind controlled study of chlormethiazole and triazolam as hypnotic in the elderly, Acta Psychiatr Scand 73, suppl 329:104–11 (1986).

    Article  Google Scholar 

  42. M. Mamelak, A. Csima, and V. Price, The effect of a single night’s dosing with triazolam on sleep the following night, J Clin Pharmacol. 30:549–55 (1990).

    Article  PubMed  CAS  Google Scholar 

  43. K. Morgan, and I. Oswald, Anxiety caused by a short-life hypnotic, Brit Med J. 284:942 (1982).

    Article  CAS  Google Scholar 

  44. A. Kales, C.R. Soldatos, E.O. Bixler, and J, D. Kales, Early morning insomnia with rapidly eliminatied benzodiazepines, Science. 220:95–7 (1983).

    Article  PubMed  CAS  Google Scholar 

  45. A. Kales, and J.D. Kales, Sleep laboratory studies of hypnotic drugs: efficacy and withdrawal effects, J Clin Psychopharmacol. 3:140–50 (1983).

    Article  PubMed  CAS  Google Scholar 

  46. C.A.L. Moon, S.I. Ankier, and G. Hayes, Early morning insomnia and daytime anxiety-a multicentre general practice study comparing loprazolam and triazolam, Brit J Clin Practice. 39:352–8 (1985).

    CAS  Google Scholar 

  47. R. Fontaine, G. Chouinard, and L. Annable, Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment, Am J Psychiatry. 141:848–852 (1984).

    PubMed  CAS  Google Scholar 

  48. A.Y. Tien, and K. Gujavarty, Seizure following withdrawal form triazolam, Am J Psychiatry. 142:1516–7 (1985).

    PubMed  CAS  Google Scholar 

  49. A.J. Heritch, R. Capwell, and P.P. Roy-Byrne, A case of psychosis and delirium following withdrawal from triazolam, J Clin Psychiatry. 48:168–9 (1987).

    PubMed  CAS  Google Scholar 

  50. D.E. Boatwright, Triazolam, handwriting, and amnestic states: two cases, J Forensic Sci. 32:1118–24 (1987).

    PubMed  CAS  Google Scholar 

  51. R.J. Shader, and D.J. Greenblatt, Triazolam and anterograde amnesia: all is not well in the z-zone, J Clin Pharmacol. 3:273 (1983).

    CAS  Google Scholar 

  52. T. Roth, K.M. Hartse, P.G. Saab, P.M. Piccione, and M. Kramer, The effects of flurazepam, lorazepam, and triazolam on sleep and memory, Psychopharmacology. 70:231–7 (1980).

    Article  PubMed  CAS  Google Scholar 

  53. M.B. Scharf, K. Fletcher, and J.P. Graham, Comparative amnestic effects of benzodiazepine hypnotic agents, J Clin Psychiatry. 49:134–7 (1988).

    PubMed  CAS  Google Scholar 

  54. H.H. Morris, and M.L. Estes, Traveler’s amnesia, transient global amnesia secondary to triazolam, JAMA. 258:945–6 (1987).

    Article  PubMed  Google Scholar 

  55. J.A. Ewing, W.J. Elliott, H.B. Radack, H.H. Morris, M.L. Estes, and M. Cohen, You don’t have to be a neuroscientist to forget everything with triazolam, but it helps, JAMA. 259:350–2 (1988).

    Article  Google Scholar 

  56. M.B. Scharf, R. Kauffman, L. Brown, J.J. Segal, and J. Hirschowitz, Morning amnestic effects of triazolam, Hillside J Clinical Psychiatry. 38-45 (1986).

    Google Scholar 

  57. A. Kales, C.R. Soldatos, E.O. Bixler, and J.D. Kales, Rebound insomnia and rebound anxiety: a review, Pharmacology. 26:121–37 (1983).

    Article  PubMed  CAS  Google Scholar 

  58. A. Kales, E.O. Bixler, A. Vela-Buena, C.R. Soldatos, D.E. Niklaus, and R.L. Manfredi, Comparison of short and long half-life benzodiazepine hypnotics: triazolam and quazepam, Clin Pharmacol Therap. 40:378–86 (1986).

    Article  CAS  Google Scholar 

  59. C. Ehrlich, California, September, 60-67 (1988).

    Google Scholar 

  60. G. Gadeholt, and O. Brørs, Tilvaerelsen med og uten Halcion, Tidsskr Nor Laegeforen 110:878 (1990).

    PubMed  CAS  Google Scholar 

  61. Arznei-Schnellinformationen, Halcion 0,5 mg Tabletten: Verzicht auf Zulassung; Halcion 0,25 mg Tabletten: Aenderung der Packungsbeilage, Bundesgesundhbl. 31:107 (1988).

    Google Scholar 

  62. Halcion 0.5 mg suspended in France, Scrip No 1189, 24, 20 maart (1987).

    Google Scholar 

  63. J.S. Schou, Triazolam: adverse effectsin relation to dosage, Pharmacol Toxicol. 64:6–8 (1989).

    Article  PubMed  CAS  Google Scholar 

  64. J.M. Leiper, and D.H. Lawson, Why do doctors not report adverse drug reactions? Neth J Med 28:546–50 (1985).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Netherlands Centre for Monitoring of Adverse Reactions to Drugs, Rijswijk, The Netherlands

    R. H. B. Meyboom M.D.

Authors
  1. R. H. B. Meyboom M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Pennsylvania, Philadelphia, Pennsylvania, USA

    Brian L. Strom

  2. University of Verona, Verona, Italy

    Giampaolo Velo

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Science+Business Media New York

About this chapter

Cite this chapter

Meyboom, R.H.B. (1992). The Triazolam Experience in 1979 in The Netherlands, a Problem of Signal Generation and Verification. In: Strom, B.L., Velo, G. (eds) Drug Epidemiology and Post-Marketing Surveillance. NATO ASI Series, vol 224. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-2587-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-2587-9_19

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-2589-3

  • Online ISBN: 978-1-4899-2587-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation